CHI Announces Roundtable Discussions to be Held at its Immunogenicity and Bioassay Summit 2016

NEEDHAM, Mass. - Sept. 22, 2016 - PRLog -- Cambridge Healthtech Institute (CHI) announced today that it will host a series of roundtable breakout discussions at its 8th annual Immunogenicity and Bioassay Summit 2016 to be held on October 26-28, 2016 at the Hyatt Regency in Baltimore, MD.

Roundtable breakout discussions include:

Meeting Regulatory Expectations Regarding Immunogenicity Assessment
Moderator: Kathleen A. Clouse, Ph.D., Director, Division of Biotechnology Review and Research 1, OBP/OPQ/CDER/FDA

Challenges in Developing Neutralizing Antibody (NAb) Assays
Moderator:  Shan Chung, Ph.D., Senior Scientist, BioAnalytical Sciences, Genentech, Inc.

Overcoming Drug Interference in ADA Assays
Moderator:  Melissa R. Snyder, Ph.D., Laboratory Director, Antibody Immunology Laboratory, Pathology and Laboratory Medicine, Mayo Clinic

Critical Issues in ADA Assay Validation
Moderator:  Jim McNally, Ph.D., Associate Director and Immunogenicity Expert, Global Early Development, Quantitative Pharmacology & Drug Disposition, EMD Serono

Practical Application of Immunogenicity Preclinical Risk Assessment
Moderator: Boris Gorovits, Ph.D., Senior Director, PDM, Pfizer, Inc.

Focus on Immunogenicity of Biosimilars
Moderator: Paul Chamberlain, NDA Advisory Board

Dealing with Pre-Existing Positive ADA Activity in Study Patients
Moderator: Li Xue, Ph.D., Principal Scientist, Pharmacokinetics Dynamics & Metabolism, NBE, Pfizer, Inc.

Product Quality Attributes and Immunogenicity
Moderator: Valerie Quarmby, Ph.D., Staff Scientist, BioAnalytical Sciences, Genentech, Inc

Current and Emerging Predictive Tools: Selecting Candidates and Predicting Clinical Outcome
Moderator: Vibha Jawa, Ph.D., Director, Biologics and Vaccines Analytics, Merck and Co. and Moderator: Tim Hickling, Ph.D., Immunogenicity Sciences Lead, Biomedicine Design, Pfizer, Inc.

Protein Design Tools for Biotherapeutic Deimmunization
Moderator: Zuben Sauna, Ph.D., Principal Investigator, Division of Hematology Research and Review, FDA/CBER

Progress towards Inducing Immunological Tolerance to Biotherapeutics
Moderator: Ronit Mazor, Ph.D., Post-Doctoral Fellow, Molecular Biology, National Cancer Institute, National Institutes of Health

Development of Mouse Models for Predictive Studies
Moderator: Michael Brehm, Ph.D., Associate Professor, Molecular Medicine, University of Massachusetts Medical School

Why Design of Experiments (DOE) Should be the First Statistical Tool in your Professional Toolbox!
Moderator: Martin Kane, MS, CRE, Managing Data Scientist, Statistical and Data Science Practice, Exponent

Considerations for Developing Potency Assays for Bispecific Antibodies
Moderator: Peter Day, Ph.D., Scientist, Genentech

A detailed agenda with times and registration details are posted at http://www.ImmunogenicitySummit.com.

About Cambridge Healthtech Institute

Cambridge Healthtech Institute (CHI) (chicorporate.com) founded in 1992, is the industry leader in providing superior-quality scientific information to eminent researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett Educational Services, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, and Cambridge Healthtech Media Group.Media.